Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: Pharmacokinetics in mice and lipophilicity

BMC Pharmacology

Volumn 12, Issue , 2012, Pages

  Munro, Thomas A ^a,b   Berry, Loren M ^c   Van't Veer, Ashlee ^a,b   Béguin, Cécile ^a,b   Carroll, F I ^d   Zhao, Zhiyang ^c   Carlezon Jr, William A ^a,b   Cohen, Bruce M ^a,b  

^a MCLEAN HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c AMGEN INC   (United States)

^d RTI INTERNATIONAL   (United States)

Author keywords

5' gnti; 5' guanidinonaltrindole; Jdtic; Jnk1; Lipophilicity; Mapk8; Nor bni; Norbinaltorphimine; P gp; Pharmacokinetics

Indexed keywords

5' GUANIDINONALTRINDOLE; KAPPA OPIATE RECEPTOR ANTAGONIST; NORBINALTORPHIMINE; UNCLASSIFIED DRUG;

ACCURACY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BRAIN HOMOGENATE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG SOLUBILITY; HUMAN; IN VIVO STUDY; LIPOPHILICITY; LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; SEDATION; SIDE EFFECT; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; BIOLOGICAL TRANSPORT; BRAIN; GUANIDINES; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INJECTIONS, INTRAPERITONEAL; LLC-PK1 CELLS; MALE; MICE; MORPHINANS; NALTREXONE; NARCOTIC ANTAGONISTS; PERMEABILITY; PIPERIDINES; RECEPTORS, OPIOID, KAPPA; SWINE; TETRAHYDROISOQUINOLINES;

EID: 84861474525     PISSN: None     EISSN: 14712210     Source Type: Journal    
DOI: 10.1186/1471-2210-12-5     Document Type: Article

References (66)

1. Knoll AT, Carlezon WA. Dynorphin, stress, and depression. Brain Res 2010, 1314:56-73. 2819644, 19782055.
2. Béguin C, Cohen BM. Medicinal Chemistry of Kappa Opioid Receptor Antagonists. Opiate Receptors and Antagonists: from Bench to Clinic 2009, 99-118. Humana Press, New York, Dean RL, Bilsky EJ, Negus SS.
3. Metcalf M, Coop A. Kappa opioid antagonists: Past successes and future prospects. AAPS J 2005, 7(3):E704-E722. 10.1208/aapsj070371, 2751273, 16353947.
4. Peters MF, Zacco A, Gordon J, Maciag CM, Litwin LC, Thompson C, Schroeder P, Sygowski LA, Piser TM, Brugel TA. Identification of short-acting κ-opioid receptor antagonists with anxiolytic-like activity. Eur J Pharmacol 2011, 661(1-3):27-34.
5. Aldrich JV, Patkar KA, McLaughlin JP. Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action. Proc Natl Acad Sci U S A 2009, 106(43):18396-18401. 10.1073/pnas.0910180106, 2775281, 19841255.
6. Portoghese PS, Nagase H, Lipkowski AW, Larson DL, Takemori AE. Binaltorphimine-related bivalent ligands and their κ opioid receptor antagonist selectivity. J Med Chem 1987, 31(4):836-841.
7. Melief EJ, Miyatake M, Carroll FI, Beguin C, Carlezon WA, Cohen BM, Grimwood S, Mitch C, Rorick-Kehn LM, Chavkin C. Duration of Action of a Broad Range of Selective Kappa Opioid Receptor Antagonists is Positively Correlated with c-Jun N-Terminal Kinase-1 Activation. Mol Pharmacol 2011, 80(5):920-929. 10.1124/mol.111.074195, 21832171.
8. Stevens WC, Jones RM, Subramanian G, Metzger TG, Ferguson DM, Portoghese PS. Potent and Selective Indolomorphinan Antagonists of the Kappa-Opioid Receptor. J Med Chem 2000, 43(14):2759-2769. 10.1021/jm0000665, 10893314.
9. Thomas JB, Atkinson RN, Vinson NA, Catanzaro JL, Perretta CL, Fix SE, Mascarella SW, Rothman RB, Xu H, Dersch CM, et al. Identification of (3R)-7-Hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide as a Novel Potent and Selective Opioid κ Receptor Antagonist. J Med Chem 2003, 46(14):3127-3137. 10.1021/jm030094y, 12825951.
10. Endoh T, Matsuura H, Tanaka C, Nagase H. Nor-binaltorphimine: a potent and selective κ-opioid receptor antagonist with long-lasting activity in vivo. Arch Int Pharmacodyn Ther 1992, 316:30-42.
11. Raehal KM, Lowery JJ, Bhamidipati CM, Paolino RM, Blair JR, Wang D, Sadee W, Bilsky EJ. In Vivo Characterization of 6β-Naltrexol, an Opioid Ligand with Less Inverse Agonist Activity Compared with Naltrexone and Naloxone in Opioid-Dependent Mice. J Pharmacol Exp Ther 2005, 313(3):1150-1162. 10.1124/jpet.104.082966, 15716384.
12. Yeung JC, Rudy TA. Sites of antinociceptive action of systemically injected morphine: involvement of supraspinal loci as revealed by intracerebroventricular injection of naloxone. J Pharmacol Exp Ther 1980, 215(3):626-632.
13. Horan P, Taylor J, Yamamura HI, Porreca F. Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test. J Pharmacol Exp Ther 1992, 260(3):1237-1243.
14. Negus S, Mello N, Linsenmayer D, Jones RM, Portoghese P. Kappa opioid antagonist effects of the novel kappa antagonist 5′-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys. Psychopharmacology 2002, 163(3):412-419. 10.1007/s00213-002-1038-x, 12373442.
15. Carroll I, Thomas JB, Dykstra LA, Granger AL, Allen RM, Howard JL, Pollard GT, Aceto MD, Harris LS. Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist. Eur J Pharmacol 2004, 501(1-3):111-119.
16. Potter DN, Damez-Werno D, Carlezon WA, Cohen BM, Chartoff EH. Repeated Exposure to the κ-Opioid Receptor Agonist Salvinorin A Modulates Extracellular Signal-Regulated Kinase and Reward Sensitivity. Biol Psychiatry 2011, 70(8):744-753. 10.1016/j.biopsych.2011.05.021, 21757186.
17. Portoghese PS, Larson DL, Jiang JB, Takemori AE, Caruso TP. 6β-[N, N-Bis(2-chloroethyl)amino]-17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan(chlornaltrexamine): a potent opioid receptor alkylating agent with ultralong narcotic antagonist actitivty. J Med Chem 1978, 21(7):598-599. 10.1021/jm00205a002, 209185.
18. Bruchas MR, Yang T, Schreiber S, DeFino M, Kwan SC, Li S, Chavkin C. Long-Acting κ Opioid Antagonists Disrupt Receptor Signaling And Produce Noncompetitive Effects By Activating c-Jun N-Terminal Kinase. J Biol Chem 2007, 282(41):29803-29811. 10.1074/jbc.M705540200, 2096775, 17702750.
19. Jackson KJ, Carroll FI, Negus SS, Damaj MI. Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse. Psychopharmacology 2010, 210(2):285-294. 10.1007/s00213-010-1803-1, 2866121, 20232057.
20. Takemori AE, Ho BY, Naeseth JS, Portoghese PS. Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J Pharmacol Exp Ther 1988, 246(1):255-258.
21. Paronis CA, Waddell AB, Holtzman SG. Naltrexone in vivo protects μ receptors from inactivation by β-funaltrexamine, but not κ receptors from inactivation by nor-binaltorphimine. Pharmacol, Biochem Behav 1993, 46(4):813-817.
22. Melief EJ, Miyatake M, Bruchas MR, Chavkin C. Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling. Proc Natl Acad Sci U S A 2010, 107(25):11608-11613. 10.1073/pnas.1000751107, 2895055, 20534436.
23. Bruchas MR, Chavkin C. Kinase cascades and ligand-directed signaling at the kappa opioid receptor. Psychopharmacology 2010, 210(2):137-147. 10.1007/s00213-010-1806-y, 20401607.
24. Berry LM, Roberts J, Be X, Zhao Z, Lin M-HJ. Prediction of Vss from In Vitro Tissue-Binding Studies. Drug Metab Dispos 2010, 38(1):115-121. 10.1124/dmd.109.029629, 19797608.
25. Kishioka S, Kiguchi N, Kobayashi Y, Ko M-C, Woods J. Pharmacokinetic evidence for the long-lasting effects of nor-binaltorphimine (nor-BNI) [abstract]. FASEB J 2012, : . 26(Meeting Abstracts):lb581. [http://www.webcitation.org/66vNGeM5x].
26. Patkar KA, Sherwood ML, Singh HD, Ross NC, McLaughlin JP. Detection of nor-BNI in mouse brain weeks after administration using LC-MS/MS [abstract]. "Therapeutic Potential of Kappa Opioids in Pain and Addiction" 2011, 30. WA, Seattle, Chavkin C, Carlezon WA, Carroll FI, Cowan A, Fields H, Shippenberg T, http://www.webcitation.org/61l4laNJr.
27. Rytting E, Lentz KA, Chen XQ, Qian F, Vakatesh S. Aqueous and cosolvent solubility data for drug-like organic compounds. AAPS J 2005, 7(1):E78-105. 10.1208/aapsj070110, 2751500, 16146352.
28. Haynes DA, Jones W, Motherwell WDS. Occurrence of pharmaceutically acceptable anions and cations in the Cambridge Structural Database. J Pharm Sci 2005, 94(10):2111-2120. 10.1002/jps.20441, 16136575.
29. Waring MJ. Lipophilicity in drug discovery. Expert Opin Drug Discov 2010, 5(3):235-248. 10.1517/17460441003605098, 22823020.
30. Thomas BF, Compton DR, Martin BR. Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency. J Pharmacol Exp Ther 1990, 255(2):624-630.
31. Avdeef A, Barrett DA, Shaw PN, Knaggs RD, Davis SS. Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates. J Med Chem 1996, 39(22):4377-4381. 10.1021/jm960073m, 8893832.
32. Friden M, Ljungqvist H, Middleton B, Bredberg U, Hammarlund-Udenaes M. Improved measurement of drug exposure in the brain using drug-specific correction for residual blood. J Cereb Blood Flow Metab 2010, 30(1):150-161. 10.1038/jcbfm.2009.200, 2949109, 19756019.
33. Maurer TS, Debartolo DB, Tess DA, Scott DO. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 2005, 33(1):175-181.
34. Friden M, Bergstrom F, Wan H, Rehngren M, Ahlin G, Hammarlund-Udenaes M, Bredberg U. Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab Dispos 2011, 39(3):353-362. 10.1124/dmd.110.035998, 21149540.
35. Friden M, Winiwarter S, Jerndal G, Bengtsson O, Wan H, Bredberg U, Hammarlund-Udenaes M, Antonsson M. Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. J Med Chem 2009, 52(20):6233-6243. 10.1021/jm901036q, 19764786.
36. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 2002, 303(3):1029-1037. 10.1124/jpet.102.039255, 12438524.
37. Shang GW, Liu DN, Yan LH, Cui XY, Zhang KP, Qi C, Chen J. Nociceptive stimulus modality-related difference in pharmacokinetic-pharmacodynamic modeling of morphine in the rat. Pharmacol Biochem Behav 2006, 85(2):464-473. 10.1016/j.pbb.2006.09.016, 17126387.
38. Kalvass JC, Olson ER, Cassidy MP, Selley DE, Pollack GM. Pharmacokinetics and Pharmacodynamics of Seven Opioids in P-Glycoprotein-Competent Mice: Assessment of Unbound Brain EC50, and Correlation of in Vitro, Preclinical, and Clinical Data. J Pharmacol Exp Ther 2007, 323(1):346-355. 10.1124/jpet.107.119560, 17646430.
39. Qi C-T, Zou H, Zhang C-H, Xie Q-L, Jin M-L, Yu L. Effect of GNTI, a kappa opioid receptor antagonist, on MK-801-induced hyperlocomotion and stereotypy in mice. Acta Pharmacol Sin 2006, 27(11):1401-1408. 10.1111/j.1745-7254.2006.00448.x, 17049114.
40. Kimura T, Higaki K. Gastrointestinal Transit and Drug Absorption. Biol Pharm Bull 2002, 25(2):149-164. 10.1248/bpb.25.149, 11853157.
41. Heilman RD, Gray MI, Chen RP, Hahn EF, Fishman J. An evaluation of the hot plate technique to study narcotic antagonists. Res Commun Chem Pathol Pharmacol 1976, 13(4):635-647.
42. Blumberg H, Dayton HB. Naloxone, naltrexone, and related noroxymorphones. Adv Biochem Psychopharmacol 1973, 8:33-43.
43. Cohen BM, Tsuneizumi T, Baldessarini RJ, Campbell A, Babb SM. Differences between antipsychotic drugs in persistence of brain levels and behavioral effects. Psychopharmacology 1992, 108(3):338-344. 10.1007/BF02245121, 1355924.
44. Manglik A, Kruse AC, Kobilka TS, Thian FS, Mathiesen JM, Sunahara RK, Pardo L, Weis WI, Kobilka BK, Granier S. Crystal structure of the μ-opioid receptor bound to a morphinan antagonist. Nature 2012, 485(7398):321-326. 10.1038/nature10954, 22437502.
45. Ward SJ, Portoghese PS, Takemori AE. Pharmacological characterization in vivo of the novel opiate, β-funaltrexamine. J Pharmacol Exp Ther 1982, 220(3):494-498.
46. Portoghese PS, Larson DL, Sayre LM, Fries DS, Takemori AE. A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities. J Med Chem 1980, 23(3):233-234. 10.1021/jm00177a002, 6245210.
47. Jiang Q, Seyed-Mozaffari A, Sebastian A, Archer S, Bidlack JM. Preventing morphine antinociceptive tolerance by irreversible mu opioid antagonists before the onset of their antagonism. J Pharmacol Exp Ther 1995, 273(2):680-688.
48. Kenakin T, Jenkinson S, Watson C. Determining the potency and molecular mechanism of action of insurmountable antagonists. J Pharmacol Exp Ther 2006, 319(2):710-723. 10.1124/jpet.106.107375, 16857731.
49. Wu H, Wacker D, Mileni M, Katritch V, Han GW, Vardy E, Liu W, Thompson AA, Huang XP, Carroll FI, et al. Structure of the human κ-opioid receptor in complex with JDTic. Nature 2012, 485(7398):327-332. 10.1038/nature10939, 22437504.
50. Kenakin T. Overview of Receptor Interactions of Agonists and Antagonists. Curr Protoc Pharmacol 2008, 42:4.1.1-4.1.24.
51. McLaughlin JP, Myers LC, Zarek PE, Caron MG, Lefkowitz RJ, Czyzyk TA, Pintar JE, Chavkin C. Prolonged Kappa Opioid Receptor Phosphorylation Mediated by G-protein Receptor Kinase Underlies Sustained Analgesic Tolerance. J Biol Chem 2004, 279(3):1810-1818. 10.1074/jbc.M305796200, 2131729, 14597630.
52. Liu-Chen LY. Agonist-induced regulation and trafficking of kappa opioid receptors. Life Sci 2004, 75(5):511-536. 10.1016/j.lfs.2003.10.041, 15158363.
53. Coller JK, Christrup LL, Somogyi AA. Role of active metabolites in the use of opioids. Eur J Clin Pharmacol 2009, 65(2):121-139. 10.1007/s00228-008-0570-y, 18958460.
54. Tiseo PJ, Geller EB, Adler MW. Antinociceptive action of intracerebroventricularly administered dynorphin and other opioid peptides in the rat. J Pharmacol Exp Ther 1988, 246(2):449-453.
55. Ross NC, Reilley KJ, Murray TF, Aldrich JV, McLaughlin JP. Novel opioid cyclic tetrapeptides: Trp isomers of CJ-15,208 exhibit distinct opioid receptor agonism and short-acting kappa opioid receptor antagonism. Br J Pharmacol 2012, 165(4b):1097-1108.
56. Trapp S, Rosania GR, Horobin RW, Kornhuber J. Quantitative modeling of selective lysosomal targeting for drug design. Eur Biophys J 2008, 37(8):1317-1328. 10.1007/s00249-008-0338-4, 2711917, 18504571.
57. Kannan P, Brimacombe KR, Kreisl WC, Liow JS, Zoghbi SS, Telu S, Zhang Y, Pike VW, Halldin C, Gottesman MM, et al. Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET. Proc Natl Acad Sci U S A 2011, 108(6):2593-2598. 10.1073/pnas.1014641108, 3038699, 21262843.
58. Heikkinen AT, Monkkonen J, Korjamo T. Kinetics of cellular retention during Caco-2 permeation experiments: role of lysosomal sequestration and impact on permeability estimates. J Pharmacol Exp Ther 2009, 328(3):882-892. 10.1124/jpet.108.145797, 19088303.
59. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010, 9(3):215-236. 10.1038/nrd3028, 3326076, 20190787.
60. Garber JC, Barbee RW, Bielitzki JT, Clayton LA, Donovan JC, Hendriksen CFM, Kohn DF, Lipman NS, Melcher J, Quimby FW, et al. Guide for the Care and Use of Laboratory Animals 2010, National Academies Press, Washington, DC, 8, http://www.webcitation.org/67NgPz8Bf.
61. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 2010, 8(6):e1000412. 10.1371/journal.pbio.1000412, 2893951, 20613859.
62. Huang L, Berry L, Ganga S, Janosky B, Chen A, Roberts J, Colletti AE, Lin M-HJ. Relationship between passive permeability, efflux, and predictability of clearance from in vitro metabolic intrinsic clearance. Drug Metab Dispos 2010, 38(2):223-231. 10.1124/dmd.109.029066, 19875499.
63. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001, 28(5):481-504. 10.1023/A:1012299115260, 11768292.
64. Zhang Y, Huo M, Zhou J, Xie S. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed 2010, 99(3):306-314. 10.1016/j.cmpb.2010.01.007, 20176408.
65. GraphPad QuickCalcs. , : . http://www.graphpad.com/quickcalcs/index.cfm, .
66. Mitchell M. Engauge digitizer 4.1. 2002, : . http://digitizer.sourceforge.net.